Boston Scientific to Acquire Bayer’s Interventional Division

In a move to significantly expand its portfolio of solutions for peripheral interventions, Boston Scientific (Natick, MA, USA) has entered into a definitive agreement to acquire the Interventional Division of Bayer (Leverkusen, Germany) for USD 415 million in cash.

The acquisition is expected to strengthen Boston Scientific’s peripheral interventions business and support the company’s strategy to expand the portfolio of peripheral vascular disease solutions, especially in the peripheral atherectomy and thrombectomy categories. Upon completion of the transaction, Bayer Interventional will become part of the existing Boston Scientific peripheral interventions business. Closing of the transaction is subject to customary conditions, including relevant antitrust clearance, and is expected to occur in the second half of 2014.

The transaction includes the AngioJet Thrombectomy System, which breaks apart and removes blood clots from within blood vessels, and the Fetch 2 Aspiration Catheter, which is used for small vessels when a manual thrombectomy device is preferred to resolve small, fresh thrombi in the peripheral and coronary arteries. The deal also includes the JetStream Atherectomy System, a versatile debulking solution for breaking apart and removing multiple lesion morphologies—from thrombus to challenging calcium deposits—from upper and lower extremity peripheral arteries.

“We expect this acquisition will help fuel continued growth for the company and we are looking forward to welcoming the team from Bayer Interventional to Boston Scientific,” said Mike Mahoney, President and CEO of Boston Scientific. “These technologies help physicians save both limbs and lives, and we believe this transaction will enable us to reach more effectively the greater than 27 million patients worldwide who suffer from the debilitating effects of peripheral vascular disease.”

“With this sale, our medical care division can concentrate on innovation and growth in radiology and diabetes care, where we already have a strong presence,” said Olivier Brandicourt, MD, CEO of Bayer HealthCare.

“The addition of Bayer Interventional will expand our commercial footprint and enhance our ability to provide physicians and healthcare systems with a complete portfolio of solutions to treat challenging vascular conditions,” added Jeff Mirviss, president of peripheral interventions at Boston Scientific. “We believe this acquisition will accelerate the growth of our Peripheral Interventions business and strengthen our position as a global leader in peripheral therapies.”

Related Links:
Boston Scientific
Bayer